You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

HPV testing to be assessed as primary screening tool for cervical cancer prevention

By Dermot - 02nd Feb 2016 | 3 views

At the request of the National Screening Service, HIQA will undertake a health technology assessment (HTA) to independently evaluate the clinical, financial, ethical and organisational implications of establishing human papillomavirus (HPV) testing as the primary screening test for preventing cervical cancer.

At present, liquid-based cytology is used as the primary screening tool by the National Cervical Screening Programme (CervicalCheck).

If low grade abnormalities are detected, the same sample is tested for HPV DNA to determine if the woman should be referred for colposcopy or back to routine screening. Using HPV DNA testing as the primary test, followed by liquid-based cytology, has the potential to improve the detection of cancerous and pre-cancerous cell changes and to increase the efficiency of the screening process.

Dr Máirín Ryan, HIQA’s Director of Health Technology Assessment, commented: “By examining international evidence on the clinical and cost-effectiveness of HPV testing — and by modelling these benefits, along with the budget impact of switching to HPV DNA testing for the Irish healthcare system — we will be in a position to provide independent advice on the optimal screening strategy for preventing cervical cancer in Ireland.”

HPV is a common virus usually spread by skin-to-skin contact during sexual contact. In most cases, it causes no symptoms and is cleared by the body’s immune system. However, persistent infection with a number of HPV virus types can lead to the development of cervical cancer.

An expert advisory group comprising key stakeholders is being formed and will advise the HTA evaluation team during the course of this assessment, according to HIQA.

The final results of the HTA, which are expected at the end of the year, will be submitted to the National Screening Service for consideration.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]